KRTX News and Press, Karuna Therapeutics Inc. From 02/26/22

As the Russian invasion of Ukraine continues, several pharma and biotech companies have exposure to both countries through clinical trials being conducted there. One biotech, Karuna Therapeutics (NASDAQ:KRTX), has already said the disturbance has impacted a late-stage trial. On Thursday, the ...

The following slide deck was published by Karuna Therapeutics, Inc. in conjunction with this event. For further details see: Karuna Therapeutics (KRTX) Presents At Annual SVB Leerink Global Health Conference

Clinical-stage biotech, Karuna Therapeutics (KRTX -10.0%) is trading sharply lower on Thursday after the company withdrew its timeline for a key data readout for a late-stage trial citing the Russian attacks on Ukraine. Previously, Karuna (NASDAQ:KRTX) indicated that the topline data from its...

Karuna Therapeutics press release (NASDAQ:KRTX): Q4 GAAP EPS of -$0.94. Revenue of $36.96M. For further details see: Karuna Therapeutics GAAP EPS of -$0.94, revenue of $36.96M

Topline data from the Phase 3 EMERGENT-2 and EMERGENT-3 trials expected in mid-2022 and in the second half of 2022, respectively Initiated the Phase 3 ARISE trial evaluating KarXT in adults with schizophrenia who inadequately respond to current standard of care in the fourth q...

Neurocrine exited 2021 with high single-digit qoq growth in Ingrezza prescriptions, but management is investing even more SG&A resources into recharging sales growth and momentum. Neurocrine has a large pipeline in terms of compounds and addressable indications, but the vast major...

Karuna Therapeutics, Inc. (NASDAQ: KRTX), a clinical-stage biopharmaceutical company driven to create and deliver transformative medicines for people living with psychiatric and neurological conditions, today announced that senior management will participate in the SVB Leerink 11th Annu...

If you're looking for stocks that can add a little excitement to your portfolio, biotech is a great place to start. Clinical-trial results and other binary events regularly send drugmaker stocks surging higher or lower overnight. If you're not sure where to start looking, you're not alo...

Karuna Therapeutics, Inc. (NASDAQ: KRTX), a clinical-stage biopharmaceutical company driven to create and deliver transformative medicines for people living with psychiatric and neurological conditions, today announced that Steve Paul, M.D., chief executive officer, president and chairm...

Although the Healthcare sector is having a positive year in absolute terms, that isn't the case in relative terms. Biotech stocks are having a difficult year, in spite of many of those trading at dirt-cheap valuations that don't even reflect the cash they have in-hand. It's very l...